Summary
Aims
Baicalin (BAI), a flavonoid compound isolated from the root of
Scutellaria baicalensis
Georgi, has been established to have potent anti‐inflammation and neuroprotective properties; however, its effects during Alzheimer's disease (
AD
) treatment have not been well studied. This study aimed to investigate the effects of
BAI
pretreatment on cognitive impairment and neuronal protection against microglia‐induced neuroinflammation and to explore the mechanisms underlying its anti‐inflammation effects.
Methods
To determine whether
BAI
plays a positive role in ameliorating the memory and cognition deficits in APP (amyloid beta precursor protein)/PS1 (presenilin‐1) mice, behavioral experiments were conducted. We assessed the effects of
BAI
on microglial activation, the production of proinflammatory cytokines, and neuroinflammation‐mediated neuron apoptosis in vivo and in vitro using Western blot,
RT
‐
PCR
,
ELISA
, immunohistochemistry, and immunofluorescence. Finally, to elucidate the anti‐inflammation mechanisms underlying the effects of
BAI
, the protein expression of
NLRP
3 inflammasomes and the expression of proteins involved in the
TLR
4/
NF
‐κB signaling pathway were measured using Western blot and immunofluorescence.
Results
The results indicated that
BAI
treatment attenuated spatial memory dysfunction in
APP
/
PS
1 mice, as assessed by the passive avoidance test and the Morris water maze test. Additionally,
BAI
administration effectively decreased the number of activated microglia and proinflammatory cytokines, as well as neuroinflammation‐mediated neuron apoptosis, in
APP
/
PS
1 mice and LPS (lipopolysaccharides)/Aβ‐stimulated
BV
2 microglial cells. Lastly, the molecular mechanistic study revealed that
BAI
inhibited microglia‐induced neuroinflammation via suppression of the activation of
NLRP
3 inflammasomes and the
TLR
4/
NF
‐κB signaling pathway.
Conclusion
Overall, the results of the present study indicated that
BAI
is a promising neuroprotective compound for use in the prevention and treatment of microglia‐mediated neuroinflammation during
AD
progression.